These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 7962302)

  • 1. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
    Gertz BJ; Barrett JS; Eisenhandler R; Krupa DA; Wittreich JM; Seibold JR; Schneider SH
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1393-7. PubMed ID: 8077339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study.
    Chapman IM; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2874-80. PubMed ID: 8768844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men.
    Kirk SE; Gertz BJ; Schneider SH; Hartman ML; Pezzoli SS; Wittreich JM; Krupa DA; Seibold JR; Thorner MO
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1154-9. PubMed ID: 9100588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men.
    Hartman ML; Farello G; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1378-84. PubMed ID: 1592884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
    Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
    Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers.
    Miell JP; Corder R; Pralong FP; Gaillard RC
    J Clin Endocrinol Metab; 1991 Mar; 72(3):675-81. PubMed ID: 1671785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy.
    Veldhuis JD; Keenan DM; Mielke K; Miles JM; Bowers CY
    Eur J Endocrinol; 2005 Oct; 153(4):577-86. PubMed ID: 16189179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles.
    Hickey G; Jacks T; Judith F; Taylor J; Schoen WR; Krupa D; Cunningham P; Clark J; Smith RG
    Endocrinology; 1994 Feb; 134(2):695-701. PubMed ID: 8299565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.